Brief: Us Based Cobra Diagnostic Prostate Cancer Trial Reaches Recruitment Target
09/02/2023 16:41
Feb 9 (Reuters) - Clarity Pharmaceuticals Ltd CU6.AX :
* US BASED COBRA DIAGNOSTIC PROSTATE CANCER TRIAL REACHES
RECRUITMENT TARGET
Source text for Eikon: ID:nPnby7VmQa
Further company coverage: CU6.AX
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Clarity Pharmaceuticals
See all newsBrief: Clarity Pharmaceuticals Signs Commercial Manufacturing Agreement
Brief: Clarity Signs A Large-Scale Manufacturing Supply Agreement For Copper-64 With Theragenics
Brief: Clarity Pharmaceuticals Signs A Large-Scale Manufacturing Supply Agreement
Australia's Clarity Pharmaceuticals rises on bagging cancer detection agent supply
Australia's Clarity Pharma surges as US FDA approves trial